Literature DB >> 26424390

From "An Enzyme Able to Destroy Penicillin" to Carbapenemases: 70 Years of Beta-lactamase Misbehaviour.

Jean-Marie Frère1, Eric Sauvage, Frédéric Kerff.   

Abstract

As early as 1940, Abraham and Chain described "an enzyme able to destroy penicillin". In the late 1940's, penicillin-resistant strains of Staphylococcus aureus were found to be a clinical problem. They produced a penicillinase that could hydrolyze the amide bond in the β-lactam ring. Later, an enzyme mediated by an R-factor was isolated from Enterobacteriaceae. Methicillin and cephalosporins, both very poor substrates of the S. aureus enzyme, were found to be sensitive to this new enzyme. Third generation cephalosporins appeared to solve the problem, but further enzymes were selected that exhibited extended spectra and could for instance hydrolyze cefotaxime and/or ceftazidime. The discovery of carbapenems constituted a major advance for our antimicrobial arsenal: they inactivated most of the essential penicillin binding proteins effectively and escaped the activity of nearly all known -β lactamases. However, the metallo-β-lactamases, which had not been recognised as a major danger before 1990, were found to act as effective carbapenemases and started to spread in a worrying way. Moreover, carbapenem-hydrolyzing enzymes were found in each of the 3 classes of active-site serine β-lactamases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26424390     DOI: 10.2174/1389450116666151001112859

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  8 in total

Review 1.  A close look onto structural models and primary ligands of metallo-β-lactamases.

Authors:  Joanna E Raczynska; Ivan G Shabalin; Wladek Minor; Alexander Wlodawer; Mariusz Jaskolski
Journal:  Drug Resist Updat       Date:  2018-08-25       Impact factor: 18.500

2.  Crystal Structure of the Pseudomonas aeruginosa BEL-1 Extended-Spectrum β-Lactamase and Its Complexes with Moxalactam and Imipenem.

Authors:  Cecilia Pozzi; Filomena De Luca; Manuela Benvenuti; Laurent Poirel; Patrice Nordmann; Gian Maria Rossolini; Stefano Mangani; Jean-Denis Docquier
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

3.  Structure-Based Virtual Screening for the Discovery of Novel Inhibitors of New Delhi Metallo-β-lactamase-1.

Authors:  Francesca Spyrakis; Giuseppe Celenza; Francesca Marcoccia; Matteo Santucci; Simon Cross; Pierangelo Bellio; Laura Cendron; Mariagrazia Perilli; Donatella Tondi
Journal:  ACS Med Chem Lett       Date:  2017-11-26       Impact factor: 4.345

4.  Discovery of the Novel Inhibitor Against New Delhi Metallo-β-Lactamase Based on Virtual Screening and Molecular Modelling.

Authors:  Xiyan Wang; Yanan Yang; Yawen Gao; Xiaodi Niu
Journal:  Int J Mol Sci       Date:  2020-05-18       Impact factor: 5.923

5.  Virtual screening identifies broad-spectrum β-lactamase inhibitors with activity on clinically relevant serine- and metallo-carbapenemases.

Authors:  Francesca Spyrakis; Matteo Santucci; Lorenzo Maso; Simon Cross; Eleonora Gianquinto; Filomena Sannio; Federica Verdirosa; Filomena De Luca; Jean-Denis Docquier; Laura Cendron; Donatella Tondi; Alberto Venturelli; Gabriele Cruciani; Maria Paola Costi
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

6.  In silico identification and experimental validation of hits active against KPC-2 β-lactamase.

Authors:  Raphael Klein; Pasquale Linciano; Giuseppe Celenza; Pierangelo Bellio; Sofia Papaioannou; Jesus Blazquez; Laura Cendron; Ruth Brenk; Donatella Tondi
Journal:  PLoS One       Date:  2018-11-29       Impact factor: 3.240

7.  IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections.

Authors:  Joseph S Solomkin; Janis Gardovskis; Kenneth Lawrence; Philippe Montravers; Angie Sway; David Evans; Larry Tsai
Journal:  Clin Infect Dis       Date:  2019-08-30       Impact factor: 9.079

Review 8.  Glycosyltransferases and Transpeptidases/Penicillin-Binding Proteins: Valuable Targets for New Antibacterials.

Authors:  Eric Sauvage; Mohammed Terrak
Journal:  Antibiotics (Basel)       Date:  2016-02-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.